Combinatorial molecular marker assays of WT1, survivin, and TERT at initial diagnosis of adult acute myeloid leukemia

European Journal of Haematology

Volumn 91, Issue 5, 2013, Pages 411-422

  Kim, Hee Je ^a   Choi, Eun Jeong ^b   Sohn, Hyun Jung ^b   Park, So Hye ^a   Min, Woo Sung ^a   Kim, Tai Gyu ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

AML; Leukemia associated antigens; Survivin; Telomerase reverse transcriptase; Wilms' tumor gene 1

Indexed keywords

ENOCITABINE; ETOPOSIDE; FERRITIN; IDARUBICIN; MITOXANTRONE; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR MARKER; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; GENDER; GENE EXPRESSION; GENE MUTATION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; SURVIVIN GENE; TERT GENE; WT1 GENE;

AML; LEUKEMIA-ASSOCIATED ANTIGENS; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; WILMS' TUMOR GENE 1;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL ASSAY; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 84885931730     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12167     Document Type: Article

References (43)

1. Miyagi T, Ahuja H, Kubonishi I, Koeffler HP, Miyoshi I. Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells. Leukemia 1993;7:970-7.
2. Ambrosini G, Adida C, Altieri DC. A novel antiapoptosis gene, surviving, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
3. Gessner A, Thomas M, Castro PG, et al. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 2010;24:1751-9.
4. Briatore F, Barrera G, Pizzimenti S, et al. Increase of telomerase activity and hTERT expression in myelodysplastic syndromes. Cancer Biol Ther 2009;8:883-9.
5. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by surviving predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-4.
6. Terwijn M, Kelder A, Rutten AP, et al. Leukemic stem cell assessment in remission bone marrow of acute myeloid leukemia patients is a new prognostic parameter. Blood 2009;114. Abstract 399.
7. Ding L, Timothy JL, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-10.
8. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008;26:5429-35.
9. Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia:a cancer and leukemia group B study. J Clin Oncol 2008;26:4595-602.
10. Menssen HD, Renkl HJ, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-7.
11. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol 2000;111:196-203.
12. - leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 2012;120:173-80.
13. Gerber JM, Qin L, Kowalski J, et al. Characterization of chronic myeloid leukemia stem cells. Am J Hematol 2011;86:31-7.
14. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001;97:2903-7.
15. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000;96:4075-83.
16. Kim HJ, Min WS, Eom KS, et al. Anti-leukaemic role of acute GvHD after unrelated haematopoietic stem cell transplantation in intermediate- to high-risk acute myelogenous leukaemia. Bone Marrow Transplant 2007;40:1069-74.
17. Park HS, Kim DW, Kim CC, et al. Induction chemotherapy with Idarubicin plus N4-behenoyl-1-b-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen-a prospective, cooperative multicenter study. Semin Hematol 1996;33(Suppl. 3):24-9.
18. Min WS, Kim HJ, Choi Y, Jeong HY, Kim CC. Interpretation of interleukin-2 receptor alpha positive cells during induction chemotherapy for adult acute myelogenous leukaemia patients. Hematol Oncol 2007;25:76-83.
19. Kim HJ, Min WS, Eom KS, et al. Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the postremission treatments in patients with adult acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2004;34:215-20.
20. Kim HJ, Min WS, Cho BS, et al. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant 2009;15:704-17.
21. Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 2006;24:1507-15.
22. Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12:1886-94.
23. Schmid D, Heinze G, Linnerth B. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-43.
24. Cilloni D, Renneville A, Hemitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet Study. J Clin Oncol 2009;27:5195-201.
25. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemia are associated with a worse long-term outcome. Blood 1997;90:1217-25.
26. Rodrigues PC, Oliveira SN, Viana MB, Matsuda EI, Nowill AE, Brandalise SR, Yunes JA. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia. Pediatr Blood Cancer 2007;49:133-8.
27. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21) (q22;q22). Blood 1997;90:1643-8.
28. Barragán E, Cervera J, Bolufer P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89:926-33.
29. Gray JX, McMillen L, Mollee P, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leuk Res 2012;36:453-8.
30. Gianfaldoni G, Mannelli F, Ponziani V, Longo G, Bencini S, Bosi A, Vannucchi AM. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010;95:833-6.
31. Galimberti S, Guerrini F, Carulli G, Fazzi R, Palumbo GA, Morabito F, Petrini M. Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis. Eur J Haematol 2004;72:45-51.
32. Kramarzova K, Stuchly J, Willasch A, et al. Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences. Leukemia 2012;26:2086-95.
33. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115-21.
34. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-704.
35. Kim YJ, Cho SG, Lee S, et al. Potential role of adoptively transferred allogeneic WT1-specific CD4(+) and CD8(+) T lymphocytes for the sustained remission of refractory AML. Bone Marrow Transplant 2003;45:597-9.
36. Yoshida A, Zokumasu K, Wano Y, et al. Marked upregulation of Survivin and Aurora-B kinase are associated with disease progression in the myelodysplastic syndromes. Haematologica 2012;97:1372-9.
37. Reis FR, Vasconcelos FC, Pereira DL, Moellman-Coelho A, Silva KL, Maia RC. Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia. Oncol Rep 2011;26:471-8.
38. Greiner J, Bullinger L, Guinn BA, Döhner H, Schmitt M. Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 2008;14:7161-6.
39. Fukuda S, Abe M, Onishi C, Taketani T, Purevsuren J, Yamaguchi S, Conway EM, Pelus LM. Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol 2011. Epub Ahead of Print.
40. Huh HJ, Huh JW, Yoo ES, Seong CM, Lee M, Hong KS, Chung WS. hTERT mRNA levels by realtime RT-PCR in acute myelogenous leukemia. Am J Hematol 2005;79:267-73.
41. Drummond MW, Balabanov S, Holyoake TL, Brummendorf TH. Concise review: telomere biology in normal and leukemic hematopoietic stem cells. Stem Cells 2007;25:1853-61.
42. Verstovsek S, Manshouri T, Smith FO, et al. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer 2003;97:2212-7.
43. Varma N, Anand MS, Varma S, Juneja SS. Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia. Leuk Lymphoma 2011;52:687-93.